Jinping Gan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5780622/publications.pdf

Version: 2024-02-01

54 papers	1,742 citations	279798 23 h-index	289244 40 g-index
55 all docs	55 docs citations	55 times ranked	2332 citing authors

#	Article	IF	Citations
1	Alternative Models in Biomedical Research: In Silico, InÂVitro, ExÂVivo, and Nontraditional InÂVivo Approaches. , 2022, , 925-966.		1
2	Hepatocyte spheroids as a viable in vitro model for recapitulation of complex in vivo metabolism pathways of loratadine in humans. Xenobiotica, 2020, 50, 621-629.	1.1	7
3	Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab on A Chip, 2020, 20, 215-225.	6.0	84
4	Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. Lab on A Chip, 2020, 20, 446-467.	6.0	66
5	Development and characterization of rat duodenal organoids for ADME and toxicology applications. Toxicology, 2020, 446, 152614.	4.2	10
6	Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metabolism and Disposition, 2020, 48, 724-734.	3.3	7
7	Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A. Drug Metabolism and Disposition, 2019, 47, 1352-1360.	3.3	13
8	Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 136-145.	2.5	38
9	Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2018, 46, 178-188.	3.3	40
10	Status and Future of 3D Cell Culture in Toxicity Testing. Methods in Pharmacology and Toxicology, 2018, , 249-261.	0.2	4
11	Synthesis and Biologic Evaluation of a Novel ¹⁸F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. Journal of Nuclear Medicine, 2018, 59, 529-535.	5.0	152
12	Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11Î²â€hydroxysteroid dehydrogenase typeâ€1 inhibitor BMSâ€823778. British Journal of Clinical Pharmacology, 2018, 84, 130-141.	2.4	11
13	LCâ€“MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drugâ€“drug interactions. Bioanalysis, 2018, 10, 1473-1485.	1.5	5
14	Strategy for the Quantitation of a Protein Conjugate via Hybrid Immunocapture-Liquid Chromatography with Sequential HRMS and SRM-Based LC-MS/MS Analyses. Analytical Chemistry, 2017, 89, 5144-5151.	6.5	14
15	Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Experimental Biology and Medicine, 2017, 242, 1579-1585.	2.4	72
16	Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 385-394.	2.5	9
17	Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metabolism and Disposition, 2017, 45, 908-919.	3.3	67
18	Drugâ€“Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization. Chemical Research in Toxicology, 2016, 29, 2040-2057.	3.3	35

#	Article	IF	Citations
19	Tissue distribution and tumor uptake of folate receptorâ€“targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharmaceutica Sinica B, 2016, 6, 460-467.	12.0	13
20	Non-cytochrome P450-mediated bioactivation and its toxicological relevance. Drug Metabolism Reviews, 2016, 48, 473-501.	3.6	26
21	Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment. Biopharmaceutics and Drug Disposition, 2016, 37, 276-286.	1.9	16
22	Ultrasensitive quantitative LCâ€“MS/MS of an inhibitor of apoptosis protein's antagonist in plasma using protein target affinity extraction. Bioanalysis, 2016, 8, 265-274.	1.5	3
23	Quantitation of repaglinide and metabolites in mouse whole-body thin tissue sections using droplet-based liquid microjunction surface sampling-high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography A, 2016, 1439, 137-143.	3.7	16
24	InÂvitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review. Chemico-Biological Interactions, 2016, 255, 23-30.	4.0	29
25	Integration of Physiologicallyâ€Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 286-294.	2.5	2
26	High-Resolution Mass Spectrometry-Based Background Subtraction for Identifying Protein Modifications in a Complex Biological System: Detection of Acetaminophen-Bound Microsomal Proteins Including Argininosuccinate Synthetase. Chemical Research in Toxicology, 2015, 28, 775-781.	3.3	11
27	Discovery of Potent Heterodimeric Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Sustained Antitumor Activity. Journal of Medicinal Chemistry, 2015, 58, 1556-1562.	6.4	16
28	Quantitative Analysis of Polyethylene Glycol (PEG) and PEGylated Proteins in Animal Tissues by LC-MS/MS Coupled with In-Source CID. Analytical Chemistry, 2014, 86, 7642-7649.	6.5	37
29	Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 330-335.	2.2	13
30	Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3914-3919.	2.2	12
31	Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metabolism and Disposition, 2013, 41, 827-835.	3.3	109
32	Identification of the Oxidative and Conjugative Enzymes Involved in the Biotransformation of Brivanib. Drug Metabolism and Disposition, 2012, 40, 219-226.	3.3	12
33	Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology. Drug Metabolism and Disposition, 2012, 40, 2374-2380.	3.3	7
34	Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((As a Potent and Selective I_{Kur} Inhibitor. Journal of Medicinal Chemistry, 2012, 55, 3036-3048.	6.4	27
35	Cytochrome P450 11A1 Bioactivation of a Kinase Inhibitor in Rats: Use of Radioprofiling, Modulation of Metabolism, and Adrenocortical Cell Lines to Evaluate Adrenal Toxicity. Chemical Research in Toxicology, 2012, 25, 556-571.	3.3	23
36	In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin. Cancer Chemotherapy and Pharmacology, 2012, 69, 51-56.	2.3	6

#	Article	IF	Citations
37	Bioactivation of Substituted Thiophenes Including Î±-Chlorothiophene-Containing Compounds in Human Liver Microsomes. Chemical Research in Toxicology, 2011, 24, 663-669.	3.3	24
38	Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate, 2011, 71, 480-488.	2.3	101
39	Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2011, 17, 880-887.	7.0	42
40	Metabolism and Disposition of [¹⁴C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans. Drug Metabolism and Disposition, 2011, 39, 891-903.	3.3	15
41	Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2). Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 423-432.	2.5	33
42	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1128-1133.	2.2	19
43	Repaglinideâ€gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. British Journal of Clinical Pharmacology, 2010, 70, 870-880.	2.4	32
44	Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors. Drug Metabolism and Disposition, 2010, 38, 1962-1966.	3.3	27
45	Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica, 2010, 40, 138-145.	1.1	13
46	Biotransformation Profiling of [14C]Ixabepilone in Human Plasma, Urine and Feces Samples Using Accelerator Mass Spectrometry (AMS). Drug Metabolism and Pharmacokinetics, 2009, 24, 511-522.	2.2	22
47	CYP3A4-Mediated Ester Cleavage as the Major Metabolic Pathway of the Oral Taxane 3â€²-tert-Butyl-3â€²-N-tert-butyloxycarbonyl-4-deacetyl-3â€²-dephenyl-3â€²-N-debenzoyl-4-O-meth (BMS-275183). Drug Metabolism and Disposition, 2009, 37, 710-718.	3.3	12
48	In Vitro Screening of 50 Highly Prescribed Drugs for Thiol Adduct Formationâ€”Comparison of Potential for Drug-Induced Toxicity and Extent of Adduct Formation. Chemical Research in Toxicology, 2009, 22, 690-698.	3.3	96
49	Troglitazone Thiol Adduct Formation in Human Liver Microsomes: Enzyme Knietics and Reaction Phenotyping. Drug Metabolism Letters, 2008, 2, 184-189.	0.8	2
50	Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. European Journal of Pharmacology, 2005, 511, 31-41.	3.5	18
51	Dansyl Glutathione as a Trapping Agent for the Quantitative Estimation and Identification of Reactive Metabolites. Chemical Research in Toxicology, 2005, 18, 896-903.	3.3	167
52	Alkylaniline-Hemoglobin Adducts and Risk of Non-Smoking-Related Bladder Cancer. Journal of the National Cancer Institute, 2004, 96, 1425-1431.	6.3	72
53	Oxidation of 2,6-Dimethylaniline by Recombinant Human Cytochrome P450s and Human Liver Microsomes. Chemical Research in Toxicology, 2001, 14, 672-677.	3.3	31
54	Protocols for Assessment ofIn vitro andIn vivo Bioactivation Potential of Drug Candidates. , 0, , 447-476.		3